Halozyme Therapeutics | HALO - Gross Profit On Sales


Halozyme Therapeutics reported $297.47M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
Baxter International USD 1.14B 251M Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 23.03M 3.84M Jun/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Eli Lilly USD 16.22B 301.7M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 265M 22M Jun/2026
MannKind USD 7.77M 60.56M Jun/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
United Therapeutics USD 683.8M 35.7M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024